Your browser doesn't support javascript.
loading
Repurposing medicinal compounds for blood cancer treatment.
McCabe, Bronagh; Liberante, Fabio; Mills, Ken I.
Afiliação
  • McCabe B; Centre for Biomedical Sciences Education, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, BT9 7AE, UK, bmccabe06@qub.ac.uk.
Ann Hematol ; 94(8): 1267-76, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26048243
ABSTRACT
Drug development is being continuously scrutinised for its lack of productivity. Novel drug development is associated with high costs, high failure rates and lengthy development process. These downfalls combined with a huge demand in blood cancer for new therapeutic treatments have led many to consider the method of drug repurposing. Finding new therapeutic indications for already established drug substances is known as redirecting, repositioning, reprofiling, or repurposing of drugs. Off-patent and on-patent drugs can be screened for additional targets and new indications thus bringing them to clinical trials at a faster pace. This approach offers smaller research groups, such as those that are academic based, into the drug development industry. Drug repurposing can make use of previously published data concerning dosage, toxicology and mechanism of activity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Hematológicas / Reposicionamento de Medicamentos / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Hematológicas / Reposicionamento de Medicamentos / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article